Cl inical Observation of Docetaxel Combined with Low2dose Cisplatin for Treating Advanced Non2small Cell Lung Cancer in Elderly Patients

Objective 　To evaluated the efficacy and toxicity of Docetaxel combined with low2dose Cisplatin as alternative chemotherapy for elderly patient s with advanced non small cell lung cancer (NSCLC) . Methods 　Thirty2one patient s were enrolled in the study. Each was t reated as following : Docetaxel 40mg/ m2 infusion once per week for two weeks ; Cisplatin 14mg/ m2 / d infusion on day1～5. Af ter 2 con2 secutive t reatment course, each for 4 weeks, evaluation of the short2term efficacy and adverse effect s was carried out . Results 　The overall response rate was 32. 3 %(10/ 31) . CR0 (0 %), PR10 (32. 3 %), SD16 (51. 6 %), PD5 (16. 1 %), median OS was 10. 3 months. Hematologic toxicities, which were mild, in2 cluded grade Ⅲ～ Ⅳ neut ropenia in 29. 0 %(9/ 31) . The major non2hematologic toxicity was weakness (45. 2 %) . Conclusion 　Weekly Docetaxel combined with low2dose Cisplatin as alternative chemotherapy is encouraging for elderly patient s with advanced NSCLC.